✦ LIBER ✦

Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients

✍ Scribed by Christian von Wagner; Samuel Smith; Steve Halligan; Alex Ghanouni; Emily Power; Richard J. Lilford; Dion Morton; Edward Dadswell; Wendy Atkin; Jane Wardle; For the SIGGAR Investigators

Book ID: 113032934
Publisher: Springer
Year: 2011
Tongue: English
Weight: 168 KB
Volume: 21
Category: Article
ISSN: 0938-7994
DOI: 10.1007/s00330-011-2154-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

YM905: Results of a randomised, double-b

YM905: Results of a randomised, double-blind placebo-controlled trial in patients with symptomatic overactive bladder

✍ L. Cardozo; I. Kuzmin; M.L. Lisee; R.J. Millard; O.B. Van Vierssen Trip; A.M. Ri 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Effect of flumazenil on the electroencep

Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial

✍ Michael Groeneweg; Klaus Gyr; Roman Amrein; Giuseppe Scollo-Lavizzari; Roger Wil 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 497 KB

Efficacy and safety of topical WBI-1001

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

✍ R. Bissonnette; Y. Poulin; Y. Zhou; J. Tan; H.C. Hong; J. Webster; W. Ip; L. Tan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB

BOTULINUM TOXIN A IS SAFE AND EFFECTIVE

BOTULINUM TOXIN A IS SAFE AND EFFECTIVE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER AND IDIOPATHIC DETRUSOR OVERACTIVITY: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

✍ A. Sahai; S. Khan; P. Dasgupta 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB